Tackling Skin Laxity and Pigmentation: Technologies in Focus at SBS 2025

At the 2025 South Beach Symposium, held from February 6-8 in Miami Beach, Florida, Michael Gold, MD, shared pearls and insights into advancements in microneedling radiofrequency (RF) devices and the aesthetic implications of GLP-1 receptor agonists. Gold spoke with Dermatology Times to share highlights from his lectures.

Gold highlighted the global surge in popularity of microneedling RF devices, stating, "Microneedling radiofrequency devices have become one of, if not, the most popular procedure globally."

He emphasized the importance of rigorous research and clinical validation, urging practitioners to ensure that companies "have real devices that actually will do something and have some data to support them."

Reflecting on his pioneering work with microneedling for acne scars around 2010-2011, Gold discussed the evolution of the technology. He introduced the concept of pulse wave technology, noting its potential to "change the game" due to the ability to utilize pulse technology to generate short pulse durations to target pigment.

This offers promising avenues for treating conditions like melasma. "We're not curing things like melasma, but we're able to treat them a lot better," Gold said.

Transitioning to the topic of GLP-1 receptor agonists, such as semaglutide, Gold acknowledged their rising prominence: "The last talk is on the most popular thing in the world right now, or at least in America, the GLP-1s."

While these medications are primarily recognized for their role in weight loss, Gold noted their role in improving conditions like psoriasis and hidradenitis supprativa, which are often worsened by comorbid obesity. Gold delved into their cosmetic effects. He addressed phenomena like "Ozempic face," characterized by facial volume loss due to rapid weight reduction, and issues like lax skin in the abdomen and upper arms. Gold emphasized the need to explore solutions for these aesthetic concerns and to understand the data supporting various therapeutic approaches.

He also touched upon the complexities surrounding the accessibility and cost of GLP-1 receptor agonists, highlighting the role of compounding pharmacies and the associated legal considerations. Gold remarked on the importance of understanding "the legal ramifications... and how this is playing a role in people being able to get these drugs, because they're very expensive."

Beyond his lectures, Gold hosted a live demonstration session, a staple of the South Beach Symposium. These sessions provided attendees with hands-on insights into the latest devices.

Stay tuned for more coverage from the South Beach Symposium, including session highlights and expert insights.